相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
S. Piperno-Neumann et al.
BRITISH JOURNAL OF CANCER (2023)
Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors
Ku-Geng Huo et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian et al.
THYROID (2022)
Small-Molecule Inhibitor Targeting Protein Kinase D: A Potential Therapeutic Strategy
Die Lv et al.
FRONTIERS IN ONCOLOGY (2021)
Dual inhibition of BRAF and MEK increases expression of sodium iodide symporter in patient-derived papillary thyroid cancer cells in vitro
Timothy M. Ullmann et al.
SURGERY (2020)
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma
Mohamad Krayem et al.
CANCERS (2020)
Head and neck paragangliomas: 30-year experience
Cristina Valero et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2020)
Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer
Fabiola Yukiko Miasaki et al.
GENES (2020)
Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification
Yanhua Bai et al.
ENDOCRINOLOGY AND METABOLISM (2020)
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A. Dunn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol
Amir Iravani et al.
THYROID (2019)
PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer
Suresh Kari et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma
K. van der Tuin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
ROS-induced near-homozygous genomes in thyroid cancer
Willem E. Corver et al.
ENDOCRINE-RELATED CANCER (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hurthle Cell Carcinoma
Raj K. Gopa et al.
CANCER CELL (2018)
Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes
Ian Ganly et al.
CANCER CELL (2018)
Coral: Clear and Customizable Visualization of Human Kinome Data
Kathleen S. Metz et al.
CELL SYSTEMS (2018)
Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer
Babs G. Sibinga Mulder et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
Marika H. Tesselaar et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2017)
Ex vivo multiplex profiling of protein tyrosine kinase activities in early stages of human lung adenocarcinoma
Stephan Arni et al.
Oncotarget (2017)
Expression of protein kinase A regulatory subunits in benign and malignant human thyroid tissues: A systematic review
Alessandro Del Gobbo et al.
EXPERIMENTAL CELL RESEARCH (2016)
Vemurafenib for BRAFV600E- positive metastatic papillary thyroid cancer
Olivier Huillard et al.
LANCET ONCOLOGY (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
Evolving molecularly targeted therapies for advanced-stage thyroid cancers
Keith C. Bible et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Near-Haploidization Significantly Associates with Oncocytic Adrenocortical, Thyroid, and Parathyroid Tumors but not with Mitochondrial DNA Mutations
Willem E. Corver et al.
GENES CHROMOSOMES & CANCER (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis
Ronald van Eijk et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Marina N. Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
T. C. Schneider et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Genome Haploidisation with Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma
Willem E. Corver et al.
PLOS ONE (2012)
Role of BRAF in Thyroid Oncogenesis
Lisa M. Caronia et al.
CLINICAL CANCER RESEARCH (2011)
Genome-wide Allelic State Analysis on Flow-Sorted Tumor Fractions Provides an Accurate Measure of Chromosomal Aberrations
Willem E. Corver et al.
CANCER RESEARCH (2008)
Partial least squares for discrimination
M Barker et al.
JOURNAL OF CHEMOMETRICS (2003)
Role of cAMP, PKA and Rap1A in thyroid follicular cell survival
AP Saavedra et al.
ONCOGENE (2002)
Controlling the false discovery rate in behavior genetics research
Y Benjamini et al.
BEHAVIOURAL BRAIN RESEARCH (2001)
Pathogenesis of thyroid nodules:: histological classification?
GB Salabè
BIOMEDICINE & PHARMACOTHERAPY (2001)
分享论文
